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Background: Primary intracoronary stent placement after successfully crossing chronic total 
coronary occlusions may decrease the high restenosis rate at long-term follow-up compared 
with conventional balloon angioplasty. 
Methods: In a prospective, randomized trial, balloon angioplasty was compared with stent 
implantation for the treatment of chronic total occlusions. Patients were followed for 12 
months with angiographic follow-up at 6 months. Quantitative coronary analysis was 
performed by an independent core lab.  
Results: A total of 200 patients were enrolled. Baseline characteristics were evenly 
distributed. After the procedure the mean minimal luminal diameter in the conventional group 
was 2.34±0.46mm versus 2.90±0.41mm in the stented group (p<0.0001). The 6-month 
angiographic follow-up showed a mean minimal luminal diameter of 1.57±0.74mm in the 
conventional group versus 1.93±0.85mm in the stented group (p=0.009) and a mean diameter 
stenosis of 44.7±25.0% versus 35.5±26.5% (p=0.036). Binary angiographic restenosis (>50% 
diameter stenosis) was seen in 33% in the conventional group versus 22% in the stented group 
(p=0.137). The reocclusion rates were 7.3% and 8.2% respectively (p=1.00). At 12 month 
follow-up, the rate of target lesion revascularization was significantly higher in the 
conventional group (29% versus 13%, p<0.0001).  
Conclusion: These data demonstrate that stenting of chronic total occlusions is superior to 
balloon angioplasty alone with a statistically significant reduction in the need for target lesion 



























STENTING OF CHRONIC TOTAL OCCLUSIONS 




   Since the introduction of percutaneous coronary intervention (PCI) by Gruentzig in 1977 1, 
this revascularization technique has been applied for an increasing number of indications. 
Chronic total occlusions were considered to be a relative contraindication for PCI because of 
a low success rate (between 51% and 73%) and a high restenosis rate (up to 68%).2-6 
Therefore many of these patients have been referred for coronary artery bypass graft surgery 
instead of balloon angioplasty. Recent studies showed an improved outcome after coronary 
stent implantation for chronic total occlusions, with restenosis rates between 32% and 55%. In 
most of these trials first generation stents were used in relatively small numbers of patients 
lacking long-term follow-up.7-12  
We performed a prospective randomized study in 200 patients with chronic total occlusions. 
The aim of our trial was to compare the immediate, 6-month, and 12-month results of balloon 
angioplasty with primary intracoronary stent placement using the NIR stent (Boston 






   The PRImary Stenting of Occluded Native coronary arteries (PRISON) study was a 
randomized, 2-center trial of 200 patients recruited between January 1998 and November 
1999. We investigated the effect of coronary NIR stent implantation versus balloon 
angioplasty in chronic coronary occlusions. Patients were included if the estimated duration 
of the chronic total occlusion was at least 2 weeks with evidence of ischemia related to the 
occluded coronary artery. Patients were excluded if the lesion could not be crossed  or if the 
target lesion length was >30mm. The study was conducted according to the principles of the 




   Chronic total coronary artery occlusion was defined by the absence of antegrade flow of 
contrast distal to the occlusion (flow grade 0 according to the Thrombolysis and Myocardial 
Infarction [TIMI] score) or only minimal flow of contrast distal to the occluded vessel (TIMI 
flow I).13 The duration of the total occlusion was estimated by clinical information, sequential 
angiographic information, or both. The estimated length of the occlusion was measured from 
the point of the chronic occlusion to the most proximal point of the distal vessel, which was 
visualized by collateral filling with contrast.  
 
Angioplasty procedure 
   Percutaneous coronary intervention was performed from either the femoral artery or radial 
artery approach with standard recanalization and stent implantation techniques. The major 
goal was to achieve a residual luminal diameter stenosis <30% on visual assessment. 
Randomization was performed after crossing the lesion, but before initial dilatation. Patients 
were randomized by a telephone allocation service, which was provided with the 
randomization list before recruitment of the first patient. Patients were equally assigned to 
either the balloon group or stent group. In all stented lesions the NIR stent (Boston Scientific) 
was used. Final dilatation was performed with high inflation pressures in all patients. At the 




All patients received aspirin before the procedure. Ticlopidine or clopidogrel was added for 1 
month for the patients who received stents. 
 
Quantitative coronary analysis 
   The angiograms were analyzed by an independent core angiography laboratory (Heart Core 
B.V., Leiden, The Netherlands). The observers were not provided with the clinical 
information of the patients. Before angiography 500 µg nitroglycerin was given intracoronary. 
The guiding catheter was used as the calibration standard. All lesions were assessed in ≥ 2 
orthogonal views and the projection showing the smallest diameter was used for quantitative 
coronary angiography analysis, and views with the least foreshortening were used for 
measuring the length of the occlusion. In disease-free proximal segments the reference 
diameter was measured. Cineangiograms were obtained before, immediately after and at 6 
months, using the same  views. Any coronary angiography performed within 3 months after 
the initial procedure was considered unscheduled. When an unscheduled angiography was 
followed by target lesion revascularization (TLR), no further angiograms were needed. If no 
TLR took place, repeat angiography at 6 months was still required. If the angiography took 
place after 3 months, 6 months angiographic assessment was not mandatory. 
The early gain was defined as the difference between the minimal luminal diameter (MLD) 
after intervention and the diameter before intervention. Late loss was defined as the 
subsequent decrease in MLD of the treated artery at the 6-month follow-up angiography. The 
loss index was defined as the late loss divided by the early gain. 
 
Long-term follow-up 
   Clinical follow-up was performed at 6 and 12 months. Repeat angina pectoris, a positive 
exercise test, or abnormal nuclear imaging were considered as clinical signs of restenosis. 
Follow-up angiography was performed earlier if there were clinical signs of restenosis and 
eventual followed by TLR. Death, myocardial infarction (MI) (defined as the presence of new  
significant Q waves or an elevation of creatine kinase or its MB isoenzyme to ≥ 2 times the 
upper limit), occurrence of angina pectoris (Canadian Cardiovascular Society class III or IV), 
or TLR (defined as percutaneous or surgical revascularization of the target lesion after the 
initial procedure) were all recorded as major adverse clinical events.  
 
Restenosis and reocclusion 
  Angiographic restenosis at follow-up was defined as > 50% residual diameter stenosis at the 
previous angioplasty site. Reocclusion was defined as a recurrent total occlusion at the 
previous angioplasty site. 
 
End-points 
   The primary end point was the binary angiographic restenosis/reocclusion rate at 6-month 
follow-up as assessed by an independent core lab. Prespecified secondary endpoints were: 
MLD and diameter stenosis at 6-month follow-up as assessed by an independent core 
laboratory and rates of TLR, MI, stroke, and death until the 12-month clinical follow-up. 
 
Statistical analysis 
   Continuous variables were expressed as mean ± SD and were compared by the paired and 
unpaired Student’s t test where appropriate; for correlations, the Pearson correlation 
coefficient (r) was computed; for categorical data, Fischer’s exact test; for ordinal data, the p  
for trend was computed. A sample size of 200 patients was calculated.  
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The formal statistical power calculation for 2 groups of 100 patients yields a power of at least 
80% for detecting a statistically significant rate difference of 19.7% for angiographic 
restenosis (that is for the rates 60.0% in the conventional balloon angioplasty group versus 
40.3% in the stent group). Taking into account 10% loss to follow-up, the power of 2 groups 
of 90 patients is at least 80% for detecting a difference of 20.7% (ie, for rates 60.0% vs 





Baseline and procedural data 
   Between January 1998 and November 1999 a total of 252 patients were screened for the 
study. Of these, 21 were excluded because the lesion could not be crossed, 14 because of 
spontaneous reperfusion to TIMI flow ≥ II in the time between the diagnostic angiogram and 
the actual procedure, and 17 for other reasons (according to the exclusion criteria). 
The baseline clinical characteristics are shown in Table 1. Most of the patients were severely 
symptomatic. 
After crossing the lesion, procedural success was achieved in all patients of the stent group. In 
the balloon group, 16 patients needed additional stent implantation due to flow impairing 
dissection or suboptimal lesion expansion. The angiographic characteristics are shown in 
Table 2. Both mean maximal balloon size and pressure were higher in the stent group 
(p<0.0001, p<0.05 respectively). There was no death,  MI, or emergency revascularization in 
either group during hospitalization. Minor bleeding occurred in 2 patients in the stent group 
and 1 patient in the balloon group. 
 
 
Table 1. Baseline Clinical Characteristics of 200 patients  
               with chronic total occlusions 
 Balloon group 









Risk factors (%) 
   Smoking 
   Diabetes mellitus 
   Hyperlipidemia* 
   Hypertension 
Previous MI (%) 
Previous intervention (%) 
   PCI 
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   Angiographic follow-up was obtained in 180 patients (90%), 16 refused (8 balloon, 8 stent), 
and angiography was not possible in 4 patients (2 deaths, 2 strokes). The quantitative 
coronary angiographic results are shown in Table 3.  
Stent implantation resulted in a larger immediate postprocedural MLD than did balloon 
angioplasty (2.90±0.41mm vs 2.34±0.46 mm, p<0.0001). Follow-up angiograms obtained at 6 
months demonstrated that patients assigned to stent implantation continued to have a larger 
MLD than those assigned to angioplasty alone (1.93±0.85 mm vs 1.57±0.74 mm, p=0.009), 
with less residual stenosis (35.5±26.5 % vs. 44.7±25.0 %, p=0.036). As a result of these 
differences, the rate of restenosis (including reocclusions) in the stent group was lower than 
that in the balloon group (21.9 % vs. 33.3 %, p=0.137). The rate of reocclusion was similar in 
both groups (8.2% vs. 7.3% respectively, p=1.000).  
 
Subanalysis 
   In the stent group the rate of TIMI 0 flow before the procedure was 61% versus 43% in the 
conventional balloon angioplasty group (p=0.02). Although the stent group showed a higher 
rate of TIMI flow grade 0, this was without causing any statistically significant imbalance. 
For patients with TIMI flow grade 0, the rate of restenosis in the stented group was 27.3% 
versus 40.0% in the balloon group (p=0.296). For patients with TIMI flow grade 1, the rate of 
restenosis was 13.8% versus 31% respectively (p=0.156).  
Occlusion duration >3 months as compared with <3 months did not predict restenosis in either 
the stent group or the balloon group (p=0.067 and p=0.194, respectively). Stratification for 
occlusion length (<10 mm, 10-20mm, >20mm) in the stent and the balloon group did not 




   Patients were followed for a mean of 13.1±2.4 months from the time of the initial 
procedure.  
TLR, which was only performed if patients reported anginal complaints and/or had a positive 
exercise test, was more frequently performed in the balloon group than in the stent group (29 
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Table 2. Angiographic characteristics of 200 patients with chronic occlusions 
 Balloon group 
(n = 100) 
Stent group 
(n = 100) 
 
p-value 
Duration of occlusion > 3 mo (%) 
Coronary artery disease (%) 
   1-vessel 
   2-vessel 
   3-vessel 
LVEF (%) 
   >50 
   20-50 
   <20 
Occluded vessel (%) 
   LAD 
   LCX 
   RCA 
Maximal balloon size (mm) 














































LVEF = left ventricular ejection fraction; LAD = left anterior descending coronary artery;  








Table 3. Quantitative coronary angiographic data 






   RD (mm) 
After procedure  
   RD (mm) 
   MLD (mm) 
   DS (%) 
At follow-up 
   RD (mm) 
   MLD (mm) 
   DS (%) 
 
Restenosis rate (% of pts) * 
Reocclusion rate (% of pts) 































































Table 4. Clinical events during follow-up 
 Balloon group 
(n = 100) 
Stent group 
(n = 100) 
  p-value 
6 month follow-up 
    
Recurrent angina CCS class (%) 
   II 
   III 
   IV 
Death 
Myocardial infarction 
Targel lesion revascularization 
   Coronary bypass surgery 
   Repeated angioplasty 
Stroke 
 
6 - 12 month follow-up 
 
Recurrent angina CCS class (%) 
   II 
   III 
   IV 
Death 
Myocardial infarction 
Target lesion revascularization 
   Coronary bypass surgery 
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   Since data from 2 landmark studies, the Belgian Netherlands Stent Study (BENESTENT) 
and the Stent Restenosis Study (STRESS)14,15, showed that coronary stenting significantly 
decreases restenosis as compared with conventional balloon angioplasty, this treatment 
modality has been suggested to be superior in an increasing number of clinical and 
angiographic indications.  
   The generally accepted indication for recanalization of a chronic total occlusion is ischemia 
related to the occluded vessel. According to the “open artery” concept, recanalization of an 
occluded coronary artery could have long-term benefits with respect to morbidity and 
mortality following MI.16,17 Opening of an “old” chronic total occlusion is also beneficial by 
restoring blood flow to a hibernating myocardium and thus improving left ventricular 
function. 18,19 
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   In a pilot study, we already showed that stenting in chronic total occlusions is safe and 
efficacious.7 Several randomized studies have been published, suggesting the superiority of 
coronary stent implantation over conventional balloon angioplasty in chronic total 
occlusions.8,9,10 In all of these studies the Palmaz-Schatz stent was used. In the Stents in Total 
Occlusion for Restenosis Prevention (STOP) and Stent versus PTCA After recanalization of  
Chronic Total Occlusion (SPACTO) trials similar results were found with the AVE 
Microstent (Medtronic, Minneapolis, Minn) and the Wiktor stent (Medtronic, San Diego, 
Calif), respectively.11,12 However, the total number of patients in these 2 trials was limited and 
randomization took place after achieving an optimal angioplasty result. 
   We studied 200 patients using the Boston Scientific NIR stent. Randomization was 
performed after crossing the occlusion with the guidewire, but before initial dilatation, 
committing operators to a treatment assignment without knowing all lesion characteristics in 
advance. Furthermore, patients were followed during a longer time period, with a mean 
follow-up of 13.1±2.4 months. 
The restenosis percentage (defined as diameter stenosis > 50%) in the present study was 33% 
in the balloon group versus 22% in the stent group. The restenosis rate in both our balloon 
group as in the stent group is lower as compared with the Stenting in Chronic Coronary 
Occlusion (SICCO; 74 vs 32%), Gruppo Italiano di Studio sullo Stent nelle Occlusioni 
Coronariche (GISSOC; 68 vs 32%), Total Occlusion Study of Canada (TOSCA; 70 vs 55%), 
SPACTO (64 vs 32%), and STOP (71 vs 42%) trials. We can think of 2 possible explanations 
for the low restenosis rate in the balloon group. First, high inflation pressures were applied in 
both treatment arms. This technique, which is known to reduce the complications of stent 
implantation20,21, might also be more effective in balloon angioplasty without the intention of 
stent implantation. The pressures in the balloon group were almost as high as in the stent 
group (12.2±3.1 atm vs 13.2±2.6 atm, respectively). The balloon angioplasty groups in most 
of the mentioned trials  received lower balloon inflation pressures than in the stent groups: 
GISSOC (7.7±2.9 atm vs 11.3±3.5 atm), TOSCA (10.0±3.3 atm vs 15.4±3.3 atm),  STOP 
(8.8±2.1 atm vs 13.2±2.5 atm), and SICCO (9.7±2.3 atm vs 9.5±3.0 atm). A second 
explanation could be the higher rate of diabetes in most of the other studies: in this study the 
rate was 11% in the balloon group and 13% in the stented group. In the other trials the rates of 
diabetes were as follows: GISSOC, 9.2% vs 11%; TOSCA, 18% vs 15%; STOP, 25% vs 
25%; and SPACTO, 32.6% vs. 35.7%.  
   The complete absence of subacute stent thrombosis was another notable result. The SICCO 
and GISSOC trials presented relatively high percentages of stent thrombosis (6.9% and 5.4%, 
respectively). Besides lower pressures, warfarin was used in stead of ticlopidine or 
clopidogrel in both studies. Today these antiplatelet agents are mandatory after coronary stent 
implantation.22-24 
   At 6-month follow-up 32% of the patients in the balloon group reported recurrent anginal 
complaints versus 21% in the stent group, which is in line with other studies. 
 
Limitations of the study 
   As in most device studies, treatment assignment could not be blinded. A bias influencing 
subsequent patient management and interpretation of anginal status could have existed. Stent 
placement could result in a more conservative management during follow-up with regard to 
TLR. An independent core laboratory, however, analyzed the angiograms. The results of our 
study cannot be extrapolated to other stent types. Other trials on chronic total occlusions, 







    These data demonstrate that stenting of CTO is superior to balloon angioplasty alone with a 
statistically significant reduction in the need for TLR and a lower, but not significant, 
restenosis rate. 
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